Clinical trial · no report yet · Phase 3
NCT05256225
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- NCT05256225 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Biospecimen Collection; Carboplatin; Computed Tomography; Echocardiography Test; High-Dose-Rate Vaginal Cuff Brachytherapy; Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Multigated Acquisition Scan; Paclitaxel; Survey Administration; Trastuzumab/Hyaluronidase-oysk
- Arms
- Arm I (paclitaxel, carboplatin) · Active comparator
- Arm II (paclitaxel, carboplatin, Herceptin Hylecta) · Experimental
- Arm III (paclitaxel, carboplatin, Phesgo) · Experimental
- Enrollment
- 360 (estimated)
- Primary outcomes
- Progression free survival
- Overall survival
- Incidence of dose limiting toxicities
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Nov 16, 2022
- Primary completion
- Oct 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05256225 · updated Oct 2, 2026
Publications
linked from the registry- Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692